New Clinical Evidence

Deltex Medical Group PLC
28 June 2007


                            Deltex Medical Group plc

       International endorsement of CardioQTM for critically ill children


28 June 2007 - Deltex Medical Group plc ('Deltex Medical' or 'Company'), the
UK's leading haemodynamic monitoring company, today announces new clinical
evidence of the value of its CardioQPTM monitoring system for the treatment of
young children in intensive care units.

The results of four studies using CardioQP in hospitals in France, the UK and
Brazil were presented this week to international doctors at the 5th World
Congress on Paediatric Critical Care in Geneva, Switzerland.

Doctors from the Hopital Arnaud de Villeneuve in Montpellier, France reported
that they had found the CardioQP to be an excellent predictor of the
fluid-responsiveness in children with low blood pressure.

Paediatric intensive care specialists from Sao Paulo, Brazil concluded that the
CardioQP 'was extremely important in the evaluation and (management) of patients
with septic shock' particularly given 'the limited forms of measuring
haemodynamic variables in paediatric intensive care units in low-income
countries.'

A team from Birmingham Children's Hospital in the UK concluded in their study
'that clinical assessment of cardiac output and systemic vascular resistance are
frequently unreliable' with doctors' own assessments agreeing with CardioQP
measurements only approximately half the time. In a second study on 20 children
in intensive care, the clinical management strategy was changed in eight of the
nine cases where CardioQP data differed from the original clinical assessment.


Deltex Medical's Chief Executive, Andy Hill commented:

'These studies reinforce the strengths of the CardioQP in the monitoring and
treatment of very sick children. It is safe, accurate, affordable and easy to
use: it allows doctors to assess childrens' haemodynamic status quickly and make
better-informed clinical decisions.

'This new clinical evidence supports further our belief that the CardioQP ought
to be made available to all doctors treating critically ill children.'


For further information, please contact:-

Deltex Medical Group plc        01243 774 837
Nigel Keen, Chairman            [e-mail]
Andy Hill, Chief Executive      [e-mail]
Ewan Phillips, Finance Director [e-mail]

Gavin Anderson & Company        020 7554 1400
Deborah Walter                  [e-mail]
Robert Speed                    [e-mail]

Charles Stanley Securities      020 7149 6457
Philip Davies                   [e-mail]
Russell Cook                    [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange